Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; the references it cites are not checked yet.

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

Open access
Herpers, Bram, Eppink, Berina, James, Mark I., Cortina, Carme, Cañellas-Socias, Adrià, Boj, Sylvia F., Hernando-Momblona, Xavier, Glodzik, Dominik, Roovers, Rob C., van de Wetering, Marc, Bartelink-Clements, Carina, Zondag-van der Zande, Vanessa, Mateos, Jara García, Yan, Kuan, Salinaro, Lucia, Basmeleh, Abdul, Fatrai, Szabolcs, Maussang, David, Lammerts van Bueren, Jeroen J., Chicote, Irene, Serna, Garazi, Cabellos, Laia, Ramírez, Lorena, Nuciforo, Paolo, Salazar, Ramon, Santos, Cristina, Villanueva, Alberto, Stephan-Otto Attolini, Camille, Sancho, Elena, Palmer, Hector G., Tabernero, Josep, Stratton, Michael R., de Kruif, John, Logtenberg, Ton, Clevers, Hans, Price, Leo S., Vries, Robert G. J., Batlle, Eduard, Throsby, Mark · 2022 · Nature Cancer

Abstract

Patient-derived organoids (PDOs) recapitulate tumor architecture, contain cancer stem cells and have predictive value supporting personalized medicine. Here we describe a large-scale functional screen of dual-targeting bispecific antibodies (bAbs) on a heterogeneous colorectal cancer PDO biobank and paired healthy colonic mucosa samples. More than 500 therapeutic bAbs generated against Wingless-related integration site (WNT) and receptor tyrosine kinase (RTK) targets were functionally evaluated by high-content imaging to capture the complexity of PDO responses. Our drug discovery strategy resulted in the generation of MCLA-158, a bAb that specifically triggers epidermal growth factor receptor degradation in leucine-rich repeat-containing G-protein-coupled receptor 5-positive (LGR5+) cancer stem cells but shows minimal toxicity toward healthy LGR5+ colon stem cells. MCLA-158 exhibits therapeutic properties such as growth inhibition of KRAS-mutant colorectal cancers, blockade of metastasis initiation and suppression of tumor outgrowth in preclinical models for several epithelial cancer types.

Overview

Integrity signals

Registry

Crossref · 10.1038/s43018-022-00359-0

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 71 · Cited by 178

Metadata

Authors
Herpers, B., Eppink, B., James, M. I., Cortina, C., Cañellas-Socias, A., Boj, S. F., Hernando-Momblona, X., Glodzik, D., Roovers, R. C., van de Wetering, M., Bartelink-Clements, C., Zondag-van der Zande, V., Mateos, J. G., Yan, K., Salinaro, L., Basmeleh, A., Fatrai, S., Maussang, D., Lammerts van Bueren, J. J., Chicote, I., Serna, G., Cabellos, L., Ramírez, L., Nuciforo, P., Salazar, R., Santos, C., Villanueva, A., Stephan-Otto Attolini, C., Sancho, E., Palmer, H. G., Tabernero, J., Stratton, M. R., de Kruif, J., Logtenberg, T., Clevers, H., Price, L. S., Vries, R. G. J., Batlle, E., & Throsby, M.
Affiliations
  • Leiden University Medical Center (NL)
  • Merus (Netherlands) (NL)
  • Institute for Research in Biomedicine (ES)
  • Vall d'Hebron Institute of Oncology (ES)
  • Vall d'Hebron Hospital Universitari (ES)
  • Institut d'Investigació Biomédica de Bellvitge (ES)
  • Wellcome Sanger Institute (GB)
  • Royal Netherlands Academy of Arts and Sciences (NL)
  • Institució Catalana de Recerca i Estudis Avançats (ES)
Corresponding author
  • Batlle, Eduard
  • Throsby, Mark
Venue
Nature Cancer
Published
2022-04-25
Volume
3
Issue
4
Pages
418-436
ISSN
2662-1347 (ISSN-L)
OpenAlex
W4224869333
Cited by
178
References
71
Citations by year
2026: 41 · 2025: 53 · 2024: 41 · 2023: 31 · 2022: 12
FWCI
19.46
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Cancer (publishedVersion)
  • PubMed (publishedVersion)
  • KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion, other-oa)
  • KNAW Research Portal (The Royal Netherlands Academy of Arts and Sciences) (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
bispecific antibodies, EGFR, Lgr5, patient-derived organoids, colorectal cancer, cancer stem cells, Wnt signaling, receptor tyrosine kinase, KRAS-mutant colorectal cancer, metastasis, epithelial tumors, patient-derived xenografts, drug discovery
MeSH terms
Humans, Imidazoles, Neoplasms, Glandular and Epithelial, Organoids, Pyrazines, Neoplastic Stem Cells, Antibodies, Bispecific, Receptors, G-Protein-Coupled, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. https://app.cochat.ai/papers/10.1038/s43018-022-00359-0
The paper
Herpers, B., Eppink, B., James, M. I., Cortina, C., Cañellas-Socias, A., Boj, S. F., Hernando-Momblona, X., Glodzik, D., Roovers, R. C., van de Wetering, M., Bartelink-Clements, C., Zondag-van der Zande, V., Mateos, J. G., Yan, K., Salinaro, L., Basmeleh, A., Fatrai, S., Maussang, D., Lammerts van Bueren, J. J., . . . Throsby, M. (2022). Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors. Nature Cancer. https://doi.org/10.1038/s43018-022-00359-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.